Loading...

ENGN ENGENE HOLDINGS INC Expansion Plans 8-K Filing

NGN

NGN

ENGENE HOLDINGS INC

(ENGN)

2025 8-K

Sales Agreement

Financial Results Announced

Loan Agreement Update

Loan Agreement Update

Financial Results Report

Public Offering Announced

Clinical Trial Update

Board Amendment Approved

Board Appointments

Management Change

Financial Results Report

Enrollment Milestone

Financial Statements

Equity Offerings

Geographic Expansion

Financial Results

Share Sale Agreement

Loan Agreement Update

Private Placement

Leadership Changes

Quarterly Results

Corporate Update

External Links:

On September 3, 2025, enGene Holdings Inc. announced it achieved its target enrollment of 100 patients for its Phase 2 LEGEND trial studying detalimogene voraplasmid for treating high-risk bladder cancer.

AI Assistant

ENGENE HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.